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Fermented Wheat Germ Extract (Avemar) in the Treatment
of Cardiac Remodeling and Metabolic Symptoms in Rats
Abishek Iyer and Lindsay Brown
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Avemar, a product of industrial fermentation of wheat germ with a standardized content of
benzoquinone and plant flavonoids, has been tested as an anti-cancer and immunomodulatory
dietary supplement. Proposed mechanisms include anti-oxidant and anti-inflammatory actions.
This study has determined whether these actions of Avemar may also be useful in the treatment
of cardiovascular diseases. Two experimental rat models of cardiovascular remodeling were
used in this project: the deoxycorticosterone acetate (DOCA)-salt-induced model of chronic
hypertension (study I) and a high-carbohydrate/high-fat diet-induced model producing chronic
symptoms of the metabolic syndrome and its associated cardiovascular complications (study II).
Our results in these rat models of hypertension and diet-induced obesity show that treatment
with Avemar improved cardiac function, decreased macrophage infiltration resulting in
decreased collagen deposition in the ventricular myocardium, reversed an increased stiffness
of the left ventricle in the diseased hearts and attenuated increased plasma malondialdehyde
concentrations. In addition to the changes in the heart, Avemar reversed glucose intolerance,
normalized systolic blood pressure and decreased visceral fat deposition in rats fed a high-fat/
high-carbohydrate diet. In conclusion, the fermented wheat germ extract Avemar has a poten-
tial role in attenuating chronic hypertension, diabetes or metabolic syndrome-induced cardio-
vascular symptoms along with metabolic abnormalities such as glucose tolerance and obesity.
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Introduction
Avemar is a product of industrial fermentation of wheat
germ with a standardized content of benzoquinone and
plant flavonoids that has been reported as safe and effec-
tive as an anti-cancer and immunomodulatory dietary
supplement (1–6). Avemar benefited patients with
stage III melanoma or colorectal cancer by increasing
progression-free survival (1,3). Avemar supplementation
reduced the incidence of treatment-related febrile neutro-
penia in children with solid cancers (7). Avemar is
currently being evaluated as a potential adjuvant thera-
peutic agent in human cancers, including those of the
breast, colon, lung and prostate, with promising results
as a supportive therapy with current anti-cancer therapies
(3,7–9). Preliminary results with Avemar supplementation
in severe rheumatoid arthritis patients showed improved
quality of life after 6 and 12 months of treatment com-
pared with baseline measurements (10, 11).
Plants have provided many possible treatment options
for human hypertension and metabolic diseases (12–17).
As with this wheat germ extract, the ingredients of the
plant extracts responsible for the therapeutic responses
are usually not known. The mechanisms which could pos-
sibly explain the responses to wheat germ extract include
inhibition of poly(ADP-ribose) polymerase (PARP),
decrease in MHC class I molecules, up-regulation of
intercellular adhesion molecule-1 (ICAM-1), regulation
of pentose phosphate pathway, inhibition of cyclooxygen-
ase isoforms and up-regulation of endogenous
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antioxidants (3,6,9,18,19). These mechanisms may also be
relevant for the treatment of cardiovascular and meta-
bolic diseases. Decreased antioxidant concentrations
resulting in oxidative stress may play an important
role in the etiology of the symptoms of cardiovascular
remodeling such as hypertension and hypertrophy; these
antioxidant concentrations may be improved by nutra-
ceuticals (20,21). Selective cyclooxygenase and PARP
inhibitors as well as antioxidant compounds have
improved cardiovascular function in myocardial ische-
mia/reperfusion injury, heart failure, cardiomyopathies,
circulatory shock, cardiovascular aging, diabetic car-
diovascular complications, myocardial hypertrophy,
atherosclerosis and vascular remodeling following injury
(22–24).
Since the progression of cardiac remodeling and
metabolic diseases is characterized by oxidative stress
and chronic inflammation, it is possible that Avemar
decreases cardiovascular remodeling, glucose intolerance
and fat deposition through its reported anti-oxidant and
anti-inflammatory properties. Thus, we have investigated
whether dietary treatment with Avemar can regulate
cardiovascular remodeling and metabolic responses in
hypertensive and diet-induced obese rats. Structural
changes in the heart were characterized by histology
and echocardiography, whereas heart function was mea-
sured in vivo using echocardiography and ex vivo in
isolated perfused hearts. Isolated thoracic rings were
used to measure vascular reactivity.
Methods
Male Wistar Rats
Male Wistar rats were bred at The University of
Queensland Biological Resources facility. All experimen-
tal protocols were approved by the Animal Experimenta-
tion Ethics Committee of The University of Queensland,
under the guidelines of the National Health and Medical
Research Council of Australia. Rats were given ad libitum
access to food and water and were housed in 12-h light/
dark conditions. Body weight, food and water intakes
were measured daily. Two experimental models of cardio-
vascular remodeling were used in this project: the deoxy-
corticosterone acetate (DOCA)-salt-induced model of
chronic hypertension (study I) and a high-carbohydrate/
high-fat diet-induced model producing chronic symptoms
of the metabolic syndrome and its associated cardiovas-
cular complications (study II).
All the rats in study I were uninephrectomized (UNX).
Rats, 8–9 weeks old, were divided into four experimen-
tal groups of eight rats each; UNX only or treated
with Avemar (4% mixture in powdered rat food;
UNXþAVE) or UNX together with DOCA (25mg in
0.4ml dimethylformamide s.c. every fourth day) and 1%
NaCl in the drinking water, with or without Avemar
treatment (DOCA and DOCAþAVE groups). For uni-
nephrectomy, rats were anesthetized with an intraperito-
neal injection of tiletamine (25mg/kg) and zolazepam
(25mg/kg, Zoletil) together with xylazine (10mg/kg,
Rompun); a lateral abdominal incision provided access
to the kidney, and the left renal vessels and ureter were
ligated. The left kidney was removed and weighed, and
the incision site was sutured. Avemar treatment was
started 4 days before surgery and continued for 28 days
until the experiments were performed (treatment for
32 days).
Study II consisted of three experimental groups of
8–9 weeks old male Wistar rats treated for 16 weeks
with corn starch (CS) (n¼ 12), cafeteriaþ beef tallow
(CAFþBT) (n¼ 12) and cafeteriaþ beef tallowþ
Avemar (CAFþBTþAVE) (n¼ 12) protocol, respec-
tively. The CAFþBT diet consisted of fructose (175 g),
powdered rat food (155 g), beef tallow (200 g), condensed
milk (395 g), Hubble, Mendel and Wakeman salt mixture
(25 g) and water (50ml) per kilogram of food. The drink-
ing water in the CAFþBT-fed rats was augmented
with 25% fructose in the water. For the control diet,
fructose and condensed milk were replaced with CS
(575 g) and BT was replaced with water (200ml).
Avemar was administered as a 4% mixture along with
CAFþBT diet for 8 weeks starting 8 weeks after the
initiation of the high-fat/high-carbohydrate diet (reversal
protocol). Daily caloric intake was calculated from the
food and water intakes using the following values
(kJ/g): fructose, 15.4; CS, 15.9; condensed milk, 13.8;
BT, 37.7 and rat food, 13.5.
Systolic blood pressure was measured in study I rats after
0, 2 and 4 weeks and in study II rats after 0, 4, 8, 12 and
16 weeks under light sedation with i.p. injection of Zoletil
(tiletamine 15mg/kg, zolazepam 15mg/kg). Measurements
were taken using an MLT1010 Piezo-Electric Pulse
Transducer (ADInstruments, Sydney, Australia) and
inflatable tail-cuff connected to a MLT844 Physiological
Pressure Transducer (ADInstruments) and PowerLab
data acquisition unit (ADInstruments).
Fasting blood glucose concentrations were measured for
study II animals with blood taken from the tail vein using
Medisense Precision Q.I.D glucose meter (Abbott
Laboratories, Bedford, USA). The rats were given 40%
glucose solution in distilled water (2 g/kg body weight)
via oral gavage. Tail vein blood samples were taken at 0,
30, 60, 90 and 120min following glucose administration.
Plasma malondialdehyde concentrations as a measure
of oxidative stress were determined in post-mortem
blood by HPLC (25).
Echocardiography
Echocardiography was performed by trained cardiac
sonographers at the Small Animal Practice, School of
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Veterinary Sciences, The University of Queensland or
The Prince Charles Hospital, Brisbane, small animal
theater. Rats were anesthetized via i.p. injection with
Zoletil (tiletamine 15mg/kg, zolazepam 15mg/kg) and
Ilium Xylazil (xylazine 10mg/kg). Echocardiographic
images of rats were obtained using the Hewlett Packard
Sonos 5500 (12MHz frequency fetal transducer) at an
image depth of 3 cm using two focal zones. Measure-
ments of left ventricular posterior wall thickness and
internal diameter were made using two-dimensional
M-Mode taken at mid-papillary level (26).
Isolated Heart Preparation
The left ventricular function of the rats in all treatment
groups was assessed using the Langendorff heart prepara-
tion. Terminal anesthesia was induced via i.p. injection
of pentobarbitone sodium 100mg/kg (Lethabarb). Once
anesthesia was achieved, heparin (1000 IU) was injected
into the right femoral vein. Isovolumetric ventricular
function was measured by inserting a latex balloon
catheter into the left ventricle connected to a Capto
SP844 MLT844 physiological pressure transducer and
Chart software on a Maclab system. All left ventricular
end-diastolic pressure values were measured by pacing
the heart at 250 beats per minute using an electrical
stimulator. End-diastolic pressures were obtained starting
from 0mmHg up to 30mmHg. The right and left ventri-
cles were separated and weighed. Diastolic stiffness con-
stant (k, dimensionless) was calculated as in previous
studies (25,27).
Organ Bath Studies
Thoracic aortic rings (4mm in length) were suspended in
an organ bath chamber with a resting tension of 10mN.
Cumulative concentration–response (contraction) curves
were measured for noradrenaline; concentration–response
(relaxation) curves were measured for acetylcholine and
sodium nitroprusside in the presence of a submaximal
(70%) contraction to noradrenaline (28).
Organ Weights
Following euthanasia, the heart, liver, kidneys, visceral
fat pads and spleen were removed and blotted dry for
weighing. All organ weights except visceral fat pads
were normalized relative to the body weight at the time
of their removal (in mg/g). Visceral fat pads were normal-
ized relative to tibial length at the time of removal
(in mg/mm).
Histology
Collagen distribution was measured in the left ventricle
following staining with picrosirius red and analyzed by
laser confocal microscopy. Tissues were initially fixed for
3 days in Telly’s fixative (100ml of 70% ethanol, 5ml of
glacial acetic acid and 10ml of 40% formaldehyde) and
then transferred into modified Bouin’s fluid (85ml of
saturated picric acid, 5ml glacial acetic acid and 10ml
of 40% formaldehyde) for 2 days. The samples were
then dehydrated and embedded in paraffin wax. Thick
sections (15 mm) were cut and stained with image analysis
under the laser scanning microscope performed as
previously described (25,29). Thin sections (10mm) of
left ventricle were cut and stained with hematoxylin and
eosin for determination of inflammatory cell infiltration.
Statistical Analysis
All data sets were represented as mean SEM. Compari-
sons or findings between groups were made via statistical
analysis of data sets using one-way/two-way analysis of
variance followed by the Duncan test to determine differ-
ences between treatment groups. A P-value 50.05 was
considered as statistically significant.
Drugs
DOCA, heparin, noradrenaline, acetylcholine and sodium
nitroprusside were purchased from Sigma Chemical
Company (St Louis, MO, USA.) The fermented wheat
germ extract, Avemar, was provided by Jenny Blyth,
Medimpex Pty Ltd, Mudgeeraba, QLD 4213, Australia
and thoroughly mixed in the food to a final concentra-
tion of 4%. Noradrenaline, acetylcholine and sodium
nitroprusside were dissolved in distilled water. DOCA
was dissolved in dimethylformamide with mild heating.
Fructose, CS and BT were obtained through The
University of Queensland Chemical Store.
Results
DOCA-salt-induced Rat Model of Cardiac
Remodeling (Study I)
Hypertension developed in DOCA-salt rats together with
an increased water intake, but these rats failed to gain
weight (Table 1). Avemar treatment did not change
systolic blood pressure and body weight but attenuated
the increased water intake (Table 1). Intake of Avemar,
calculated from the daily food intake, was not signifi-
cantly different between the treated groups: 2.4 0.1
(UNXþAVE) and 2.3 0.3 (DOCAþAVE) g/kg body
wt/day, respectively. Plasma malondialdehyde concentra-
tions, as a measure of oxidative stress, were increased in
DOCA rats; this increase was attenuated by Avemar
treatment (Table 1).
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Cardiac Structure and Function
Hearts from DOCA-salt rats showed marked cardiac
hypertrophy, as evidenced by increased left ventricular
wet weight relative to body weight and left ventricular
mass derived from echocardiography (Table 1). This
was associated with a decrease in left ventricular internal
diameter, indicating concentric cardiac hypertrophy
(Table 1). Avemar failed to alter the decrease in left
ventricular chamber diameter (Table 1). Additionally,
the relative wet weights of the liver, spleen and the
remnant kidney from DOCA-salt rats were increased
(Table 1). Treatment with Avemar failed to attenuate
the increased wet weights of the ventricles and the rem-
nant kidney. Increased wet weight of both liver and
spleen were attenuated with Avemar treatment (Table 1).
Echocardiographic assessment of heart function showed
that Avemar attenuated the increase in relative wall
thickness observed in DOCA-salt rats (Table 1). Further-
more, aortic blood flow velocities were increased and
cardiac output was decreased in DOCA-salt rats;
Avemar prevented the increase in blood flow velocities
but failed to improve cardiac output (Table 1).
Functionally, the increased diastolic stiffness in isolated
hearts from DOCA-salt rats was prevented by Avemar
treatment (Table 1). Furthermore, both interstitial
and perivascular collagen deposition was increased in
the left ventricle of DOCA-salt rats compared to the
UNX rats; this deposition was markedly attenuated
by Avemar treatment (Table 1 and Fig. 1). Spatial
location of monocyte/macrophages determined by
hematoxylin and eosin (H&E) staining (Fig. 1) showed
monocyte/macrophages in the left ventricle of UNX rats
in very low numbers and always as single cells. The den-
sity of monocyte/macrophages found in the left ventricle
of DOCA-salt rats was significantly greater than in
UNX, and these cells were usually found in clusters of
cells located at scar sites and throughout the interstitium
and the areas of fibrosis. Very few infiltrating cells were
found in scar tissue in DOCA-salt rats treated with
Avemar, predominantly due to the decreased area of
scar tissue within the left ventricle; few infiltrating cells
were found in the perivascular areas (Fig. 1).
Vascular Function
In isolated thoracic aortic rings, DOCA-salt rats showed
decreased contractile responses to noradrenaline
(Fig. 2A), unaltered responses to sodium nitroprusside
(Fig. 2B) together with endothelial dysfunction, defined
as decreased relaxation responses to acetylcholine
(Fig. 2C). Treatment with Avemar failed to normalize
these decreased responses (Fig. 2A and C).
High-carbohydrate/High-fat Diet-induced Model of
Cardiac Remodeling and Metabolic Changes (Study II)
Young male Wistar rats fed a high-carbohydrate/high-
fat diet showed increased body weight, especially with
increased abdominal fat pads, compared with CS-fed
rats, without an increased food intake (Table 2). Caloric
intake was similar in both diets with CS-fed rats averaging
408 38 kJ/day, whereas CAFþBT-fed rats averaged
381 47 kJ/day. Treatment with Avemar reversed the
Table 1. Physiological parameters of UNX, UNXþAVE, DOCA and DOCAþAVE-fed rats
Parameter UNX (4 weeks) UNXþAVE (4 weeks) DOCA (4 weeks) DOCAþAVE (4 weeks)
Daily water intake (ml) 67 11 (n¼ 6) 59 9 (n¼ 6) 190 33* (n¼ 6) 125 30** (n¼ 6)
Daily food intake (g) 29 2 (n¼ 6) 27 3 (n¼ 6) 24 5 (n¼ 6) 23 5 (n¼ 6)
Systolic blood pressure (mmHg) 0 week 107 1.3 (n¼ 6) 113 1.8 (n¼ 6) 108 3.1 (n¼ 6) 105 2.1 (n¼ 6)
Systolic blood pressure (mmHg) 2 weeks 128 0.7 (n¼ 6) 145 6* (n¼ 6) 176 7.0* (n¼ 6) 171 6.0* (n¼ 6)
Systolic blood pressure (mmHg) 4 weeks 135 1.7 (n¼ 6) 151 1.0* (n¼ 6) 186 3.6* (n¼ 6) 182 3.0* (n¼ 6)
LVIDd (cm) 0.66 0.01 (n¼ 6) 0.57 0.01* (n¼ 6) 0.48 0.02* (n¼ 6) 0.51 0.01* (n¼ 6)
LVPWd (cm) 0.15 0.01 (n¼ 6) 0.17 0.01 (n¼ 6) 0.22 0.01* (n¼ 6) 0.22 0.01* (n¼ 6)
Fractional shortening (%) 54 6 (n¼ 6) 57 1.4 (n¼ 6) 58 3 (n¼ 6) 64 5 (n¼ 6)
LV mass (g) 0.7 0.01 (n¼ 6) 0.63 0.01 (n¼ 6) 0.85 0.01* (n¼ 6) 0.75 0.01** (n¼ 6)
Cardiac output (ml/min) 56 9 (n¼ 6) 39 8 (n¼ 6) 21 3* (n¼ 6) 27 8* (n¼ 6)
Ejection fraction (%) 87 3 (n¼ 6) 92 0.7 (n¼ 6) 92 2 (n¼ 6) 92 1.4 (n¼ 6)
Relative wall thickness 0.49 0.01 (n¼ 6) 0.94 0.2* (n¼ 6) 1.49 0.68* (n¼ 6) 0.94 0.2** (n¼ 6)
LV interstitial collagen (% of total area) 2.7 0.3 (n¼ 5) 2.4 0.5 (n¼ 5) 11.7 1.3* (n¼ 6) 3.8 0.7** (n¼ 5)
LV perivascular collagen (% of total area) 25.6 0.9 (n¼ 4) 26.2 1.1 (n¼ 4) 36.4 1.3* (n¼ 4) 28.1 1.0** (n¼ 4)
Diastolic stiffness constant (k) 20.3 0.8 (n¼ 6) 19.7 1.8 (n¼ 6) 32.3 1.7* (n¼ 6) 22.6 0.7** (n¼ 6)
LVþ septum (mg/g body wt) 2.16 0.1 (n¼ 6) 2.0 0.1 (n¼ 6) 3.06 0.08* (n¼ 6) 2.9 0.1* (n¼ 6)
RV (mg/g body wt) 0.36 0.01 (n¼ 6) 0.51 0.01* (n¼ 6) 0.49 0.01* (n¼ 6) 0.54 0.01* (n¼ 6)
Liver (mg/g body wt) 28.2 1.7 (n¼ 6) 40.6 1.4 (n¼ 6) 54 2.0* (n¼ 6) 45.6 3** (n¼ 6)
Spleen (mg/g body wt) 2.4 0.17 (n¼ 6) 2.4 0.1 (n¼ 6) 4.3 0.2* (n¼ 6) 3.1 0.1** (n¼ 6)
Remnant kidney (mg/g body wt) 5.1 0.4 (n¼ 6) 4.0 0.5 (n¼ 6) 8.2 0.3* (n¼ 6) 9.3 0.5* (n¼ 6)
Plasma malondialdehyde (MDA)
concentration (mmol/l)
19.7 0.7 (n¼ 6) 20.4 0.6 (n¼ 6) 27.3 0.8* (n¼ 6) 23.9 0.6** (n¼ 6)
Values are mean SEM; number of experiments in parentheses. LV, left ventricle; RV, right ventricle; LVIDd, left ventricular internal diameter at
diastole; LVPWd, left ventricular posterior wall thickness at diastole. LV mass calculated according to (26).
*P50.05 versus UNX; **P50.05 versus DOCA.
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increase in body weight and abdominal fat pads compared
to the CAFþBT-fed rats. Measurement of blood glucose
concentrations after administration of a loading dose of
glucose showed that CAFþBT-fed rats were glucose-
intolerant as the blood glucose concentrations reduced
much more slowly than in the corn starch-fed rats
(Table 2). Treatment with Avemar normalized the glucose
tolerance compared with CAFþBT-fed rats (Table 2).
Cardiac Structure and Function
Systolic blood pressure increased in CAFþBT-fed rats
over the first 4 weeks and was then maintained over
the next 12 weeks with mean values of 141 6mmHg
at 8 weeks and 146 4mmHg at 16 weeks. In contrast,
the systolic blood pressure in corn starch-fed rats
was unchanged at 115 3mmHg at 8 weeks and
117 4mmHg at 16 weeks (Fig. 3). Initiating treatment
with Avemar after 8 weeks of CAFþBT feeding
decreased blood pressure to 131 1mmHg at 12 weeks
and 120 2mmHg at 16 weeks (Fig. 3). Echocardio-
graphic assessment of CAFþBT-fed rats in vivo indi-
cated ventricular dilatation (increased internal diameter
in diastole) with increased ventricular mass and left
ventricular systolic volume but with decreased contractil-
ity shown as a decreased fractional shortening and ejec-
tion fraction (Table 2). CAFþBT-fed rats showed
decreased mitral valve flow rates [evaluated as a ratio
of the flow rate (E/A)] compared with the corn starch-
fed rats (Table 2). Ex vivo cardiac function as measured
in the Langendorff isolated heart showed a markedly
increased cardiac stiffness (Table 2). These changes in car-
diac structure and function were attenuated by Avemar
treatment in the CAFþBT-fed rats (Table 2).
Figure 1. Picrosirius red staining of left ventricular interstitial collagen deposition (magnification, 40) in UNX (A), DOCA (B), UNXþAVE (C),
DOCAþAVE (D)-treated rats and hematoxylin and eosin staining of infiltrating inflammatory cells of left ventricular interstitial region (magnifica-
tion, 40) in UNX (E), DOCA (F), UNXþAVE (G), DOCAþAVE (H)-treated rats; collagen is stained light red.
Figure 2. Cumulative concentration–response curves for noradrenaline (A), sodium nitroprusside (B) and acetylcholine (C) in thoracic aortic rings
from UNX (filled square), UNXþAVE (open square), DOCA (filled circle) and DOCAþAVE (open circle)-fed rats after 16 weeks of feeding.
*P50.05 versus UNX.
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Organ remodeling and oxidative stress
Post-mortem organ weights showed a selective increase
in left ventricular wet weight and kidney weights com-
pared with the right ventricle and other major organs
in CAFþBT-fed rats compared with corn starch-fed
rats (Table 2). Avemar administration reversed this
organ hypertrophy in CAFþBT-fed rats. Spatial loca-
tion of monocyte/macrophages determined by H&E
staining (Fig. 4) shows more monocyte/macrophages in
the left ventricle of the CAFþBT rats than in corn
starch-fed rats, and these cells were usually found in clus-
ters of cells in the interstitial and perivascular regions of
fibrosis (Table 2 and Fig. 4). Furthermore, both intersti-
tial and perivascular collagen deposition was markedly
increased in the left ventricle of CAFþBT-fed rats com-
pared to the corn starch-fed rats (Table 2 and Fig. 4).
Plasma malondialdehyde concentrations, as a marker of
oxidative stress, were increased with CAFþBT feeding.
Avemar treatment attenuated these increases in ventricu-
lar collagen deposition and plasma malondialdehyde
concentrations (Table 2).
Vascular Responses
Vascular responses to noradrenaline were unchanged by
CAFþBT feeding. Responses to sodium nitroprusside
(endothelium-independent relaxation) were decreased by
CAFþBT feeding (Fig. 5A and B). CAFþBT feeding
induced endothelial dysfunction, shown as decreased
responses to the endothelium-dependent relaxant, acetyl-
choline (Fig. 5C). Treatment with Avemar failed to
normalize this decreased response to acetylcholine but
normalized the decreased response to sodium nitroprus-
side (Fig. 5B and C). Furthermore, Avemar-treated rats
showed decreased responses to noradrenaline compared
with corn starch and CAFþBT-fed rats (Fig. 5A).
Table 2. Physiological parameters of CS, CAF+BT and CAF+BT+AVE-fed rats
Parameter Corn starch
(16 weeks)
CAFþBT
(8 weeks)
CAFþBT
(16 weeks)
CAFþBTþAVE
(16 weeks)
Body weight (g) 341 13 (n¼ 8) 448 11 (n¼ 8) 523 14 (n¼ 8) 479 8 (n¼ 8)
Daily water intake (ml) 24.0 2.4 (n¼ 6) 19.1 3.0 (n¼ 6) 21.6 4.0 (n¼ 6) 19.0 3 (n¼ 6)
Daily food intake (g) 29.0 4.3 (n¼ 6) 26.1 2.8 (n¼ 6) 22.4 1.8 (n¼ 6) 22.0 4 (n¼ 6)
Daily drug intake (g/kg/day) N/A N/A N/A 1.83 0.25 (n¼ 6)
Fasting plasma glucose concentrations (mmol/l) 3.2 0.5 (n¼ 6) 3.5 0.1 (n¼ 6) 4.0 0.1* (n¼ 6) 3.6 0.1** (n¼ 6)
Plasma glucose concentration (mmol/l)
(after 120min glucose loading)
6.0 0.4 (n¼ 4) 5.9 0.2 (n¼ 6) 7.0 0.4* (n¼ 6) 4.4 0.2** (n¼ 6)
LVIDd (cm) 0.61 0.02 (n¼ 6) 0.78 0.01* (n¼ 8) 0.76 0.02* (n¼ 8) 0.73 0.01* (n¼ 8)
LVPWd (cm) 0.18 0.01 (n¼ 4) 0.16 0.01 (n¼ 8) 0.20 0.01 (n¼ 8) 0.17 0.01 (n¼ 8)
Fractional shortening (%) 63 2 (n¼ 4) 44 2* (n¼ 8) 35 1* (n¼ 8) 54 2** (n¼ 8)
Mitral valve flow rate (E/A) ratio 2.1 0.1 (n¼ 6) 1.8 0.1 (n¼ 6) 1.1 0.01* (n¼ 6) 1.4 0.12** (n¼ 6)
Estimated LV mass (g) 0.82 0.06 (n¼ 4) 0.88 0.03 (n¼ 8) 1.01 0.05* (n¼ 8) 0.82 0.03** (n¼ 8)
LV systolic volume (ml) 0.046 0.01 (n¼ 5) 0.09 0.01* (n¼ 8) 0.127 0.01* (n¼ 8) 0.040 0.01** (n¼ 8)
Cardiac output (ml/min) 93 6 (n¼ 4) 98 7 (n¼ 8) 83 9 (n¼ 8) 105 6 (n¼ 8)
Ejection fraction (%) 95 0.9 (n¼ 4) 81 2* (n¼ 8) 72 1* (n¼ 8) 90 0.9** (n¼ 8)
Relative wall thickness 0.55 0.04 (n¼ 4) 0.41 0.01* (n¼ 8) 0.51 0.04 (n¼ 8) 0.45 0.01** (n¼ 8)
LV interstitial collagen (% of total area) 4.8 0.5 (n¼ 4) 14.6 1.4* (n¼ 4) 19.9 1.2* (n¼ 4) 8.4 0.4** (n¼ 4)
LV perivascular collagen (% of total area) 21.2 1.6 (n¼ 4) 31.2 2.6* (n¼ 4) 35.3 3.0* (n¼ 4) 26.1 1.2** (n¼ 4)
Diastolic stiffness constant (k) 20.5 0.4 (n¼ 4) 26.3 2.2* (n¼ 6) 27.8 1.5* (n¼ 6) 21.6 1.4** (n¼ 6)
LVþ septum (mg/g body wt) 1.9 0.2 (n¼ 4) 2.1 0.03 (n¼ 8) 2.2 0.07 (n¼ 8) 1.7 0.1** (n¼ 8)
RV (mg/g body wt) 0.53 0.03 (n¼ 4) 0.41 0.01* (n¼ 8) 0.43 0.02* (n¼ 8) 0.44 0.02* (n¼ 8)
Liver (mg/g body wt) 26.7 0.6 (n¼ 4) 28.2 1.4 (n¼ 8) 29.9 0.95 (n¼ 8) 23.1 0.02** (n¼ 6)
Spleen (mg/g body wt) 2 0.1 (n¼ 4) 1.8 0.03 (n¼ 8) 1.68 0.1 (n¼ 8) 1.75 0.23 (n¼ 8)
Left and right kidney (mg/g body wt) 5.15 0.1 (n¼ 4) 6.3 0.2* (n¼ 8) 5.94 0.12* (n¼ 8) 5.13 0.39** (n¼ 8)
Abdominal fat pads (mg/mm tibial length) 401 56 (n¼ 6) 343 25 (n¼ 8) 826 62* (n¼ 8) 339 31** (n¼ 8)
Plasma malondialdehyde (MDA) concentration (mmol/l) 26.9 0.7 (n¼ 5) 29.4 0.5* (n¼ 5) 32.2 1.2* (n¼ 5) 28.8 0.6** (n¼ 5)
Values are mean SEM; number of experiments in parentheses. LV, left ventricle; RV, right ventricle; LVIDd, left ventricular internal diameter at
diastole; LVPWd, left ventricular posterior wall thickness at diastole. LV mass calculated according to (26).
*P50.05 versus CS; **P50.05 versus CAFþBT.
Figure 3. Tail-cuff measurement of systolic blood pressure recorded at
0, 4, 8, 12 and 16 weeks for corn starch (filled square), CAFþBT (filled
circle) and CAFþBTþAVE (open circle)-fed rats. *P50.05 versus
corn starch-fed rats; #P50.05 vs. CAFþBT-fed rats.
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Discussion
In the DOCA-salt rat model of hypertension, we have
shown that treatment with Avemar improved cardiac
function, decreased macrophage infiltration resulting in
decreased collagen deposition in the ventricular myocar-
dium, reversed an increased stiffness of the left ventricle
in the diseased hearts and attenuated oxidative stress
measured as plasma malondialdehyde concentrations
without changing systolic blood pressure. Our previous
studies have shown similar results with inhibitors of the
renin–angiotensin system (captopril, candesartan and
spironolactone) (27). In contrast, we showed that treat-
ment of DOCA-salt rats with L-arginine also decreased
blood pressure in the DOCA-salt hypertensive rat (19). In
the current study, we have further shown that Avemar
reversed glucose intolerance, normalized blood pressure
and decreased visceral fat deposition in rats fed a high-
fat/high-carbohydrate diet.
Since the mechanisms for these cardiovascular
actions may be an extension of the anti-oxidant, anti-
inflammatory and immunomodulatory mechanisms
proposed for the anti-cancer actions of Avemar, it is
worthwhile considering whether these actions improve
cardiovascular function in disease models (Fig. 6).
Avemar produced non-specific inhibition of both cyclo-
oxygenase isoforms, with IC50 values on COX-1 and
COX-2 of 100 mg/ml and 300 mg/ml, respectively (30). In
animal studies, COX inhibition decreased myocardial
infarct size (24), produced scar thinning (31,32), attenu-
ated cardiopulmonary dysfunction during endotoxemia
(31,32) and prevented angiotensin II-induced produc-
tion of superoxide in cardiovascular tissue, together
with the decrease in systolic blood pressure and cardiac
Figure 4. Picrosirius red staining of left ventricular interstitial collagen deposition in corn starch (16 weeks) (A), CAFþBT (8 weeks) (B), CAFþBT
(16 weeks) (C) and CAFþBTþAVE (16 weeks) (D)-treated rats and hematoxylin and eosin staining of infiltrating inflammatory cells of left
ventricular interstitial region (magnification, 40) CS (16 weeks) (E), CAFþBT (8 weeks) (F), CAFþBT (16 weeks) (G) and CAFþBTþAVE
(16 weeks)-treated (H) rats; collagen is stained light red.
Figure 5. Cumulative concentration–response curves for noradrenaline (A), sodium nitroprusside (B), and acetylcholine (C) in thoracic aortic rings
from corn starch (filled square), CAFþBT (filled circle) and CAFþBTþAVE (open circle)-fed rats after 16 weeks of feeding. *P50.05 versus corn
starch-fed rats.
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hypertrophy in vivo (33). Arachidonic acid metabolites
are important mediators of inflammation in cardiovascu-
lar remodeling; arachidonic acid is released from mem-
branes by phospholipase A2. Inhibition of phospholipase
A2 with KH064 prevented an increase in infiltration
of inflammatory cells, myocardial collagen deposition
and ventricular stiffness in young spontaneously hyper-
tensive rats (29). Thus, the decreased collagen deposition
following Avemar treatment could be mediated by these
known actions as inhibitors of the production of arachi-
donic acid metabolites. Further, Avemar decreased
inflammation through other immunomodulatory mecha-
nisms, such as decreased production of pro-inflammatory
cytokines IL-6 and IL-10 in mice with systemic lupus
erythematosus (20,34) and decreased macrophage infiltra-
tion in animal models of rheumatoid arthritis (20,34).
Thus, the proposed mechanisms for the anti-cancer
effects of Avemar may contribute to the cardiovascular
responses in this study.
Furthermore, Avemar contains compounds such as
benzoquinones and other plant flavonoids, important
agents in controlling oxidative stress and cell damage
(19,34). There is extensive literature on the therapeutic
use of antioxidant compounds to improve cardiovascular
function (20,21). Epidemiological comparisons between
populations and studies within populations also support
the contention that high plasma concentrations or
increased dietary intake of natural antioxidant vitamins
may protect against the development of cardiovascular
diseases in humans (20). Thus, an improvement in oxida-
tive status following Avemar treatment may improve
cardiovascular function.
Since inflammatory mediators are important in fat
deposition (35), the anti-inflammatory mechanisms
underlying the anticancer effects of Avemar may also
decrease abdominal fat deposition. Furthermore, peroxi-
some proliferator-activated receptor d (PPARd) is of
central importance in fat oxidation (35–37). Flavonoids
and phenolic acids decreased intracellular triglyceride
and glucose phosphate dehydrogenase activity through
down-regulating expression of adipogenic transcription
factors such a PPARd and up-regulating adiponectin
expression (38). The decrease in fat deposition and
weight gain in the rats fed with a high-carbohydrate/
high-fat diet with Avemar treatment could be explained
by the actions of flavonoids possibly modulating adipo-
genic transcription factors.
Similarly, the anti-inflammatory mechanisms useful in
treatment of cancer may contribute to the changes in
glucose tolerance in the high-carbohydrate/high fat diet
rats treated with Avemar (39,40). Antioxidants such as
N-acetylcysteine, vitamin C and E have also shown anti-
diabetic effects possibly by protecting pancreatic b-cells
from glucose toxicity, stimulating insulin secretion and
moderately reducing blood glucose levels (41–43). One
of the consequences of elevated blood glucose concentra-
tions is the non-enzymatic glycation of proteins such
as hemoglobin A1c (HbA1c) and serum albumin (44).
Plant flavonoids inhibited fructose-mediated glycation
of albumin improving the symptoms of diabetes (44).
Other components of Avemar such as the benzoqui-
nones may also be cardioprotective. Benzoquinones have
very similar characteristics to vitamins and are anti-
oxidant compounds. Coenzyme Q10 (ubiquinone) is a
naturally occurring benzoquinone, which may prevent
cellular damage during myocardial ischemia and reperfu-
sion by its roles in oxidative phosphorylation and
membrane stabilization (45); diabetes induced a decrease
in coenzyme Q plasma levels (46). Coenzyme Q10 and
alpha-tocopherol treatment decreased glycated HbA1c
and pancreatic lipid peroxidation in diabetic rats (40).
Coenzyme Q10 has also been used in oral form to treat
various cardiovascular disorders including angina pec-
toris, hypertension and congestive heart failure (45,47).
In conclusion, our results show that the fermented
wheat germ extract Avemar has a potential role to
attenuate the cardiovascular symptoms induced by hyper-
tension, diabetes or the metabolic syndrome while
moderating metabolic abnormalities such as glucose
tolerance and obesity. Since Avemar is already available
in humans as a complementary therapy for cancer, this
product could be further evaluated in a clinical setting as
an adjunct therapy for preventing cardiovascular and
metabolic symptoms.
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